Expansion of GLP-1 access through established telehealth platforms increases prescriber options for medication initiation and management, particularly relevant for family medicine practices seeking to integrate GLP-1 therapy into their workflows with established regulatory frameworks. This development affects prescribing patterns and patient access channels that clinicians must understand when counseling patients on treatment modalities and monitoring requirements. Understanding the landscape of GLP-1 distribution channels enables family physicians to better coordinate care and ensure consistent clinical oversight regardless of where patients obtain their medications.

Hims & Hers Health Inc. has expanded its telehealth platform to include Eli Lilly’s complete portfolio of FDA-approved GLP-1 receptor agonists for weight management, including Zepbound (tirzepatide). This expansion represents a significant shift in accessibility of GLP-1 therapies through direct-to-consumer telehealth channels, complementing the existing GLP-1 offerings already available through various telehealth platforms. The availability of Lilly’s GLP-1 agents through this established telehealth infrastructure broadens treatment options for prescribers managing patients seeking weight loss interventions and may enhance patient access to agents with demonstrated efficacy in weight reduction and metabolic improvement.

For clinical practitioners, this expansion increases the pharmacotherapeutic options available through telehealth channels and reflects the growing integration of GLP-1 weight loss treatments into mainstream medical practice outside traditional in-office settings. Prescribers should remain cognizant that telehealth-based GLP-1 prescribing requires the same clinical evaluation and monitoring protocols as in-office prescribing, including baseline metabolic assessment, contraindication screening, and ongoing tolerance and efficacy monitoring. The availability of tirzepatide through this platform provides an additional agent with dual GLP-1 and GIP receptor agonism, which may offer distinct pharmacologic advantages for selected patients compared to GLP-1 monotherapy.

This platform expansion underscores the continued evolution of telehealth delivery models for weight management pharmacotherapy and highlights the role of direct-to-consumer platforms in medication distribution. Clinicians prescribing through telehealth should ensure adherence to state-specific regulations, appropriate documentation of medical necessity, and continuity of care coordination with the patient’s primary care provider when applicable.

Clinical Takeaway

Hims & Hers now offers Eli Lilly’s GLP-1 medications including Zepbound through their telehealth platform, expanding access to FDA-approved weight loss treatment options. This expansion allows patients to obtain GLP-1 therapy through remote consultation rather than in-person office visits. For family medicine practices, this represents an important competitive landscape shift where patients may seek GLP-1 therapy through digital-first platforms rather than traditional care settings. When discussing GLP-1 options with patients, clarify your practice’s prescribing protocols, medication sourcing standards, and follow-up monitoring plans to help patients understand the clinical advantages of office-based management over telehealth-only models.

“The expansion of GLP-1 access through telehealth platforms like Hims & Hers reflects a necessary democratization of these medications, though it underscores the critical importance of proper patient screening and ongoing monitoring that telehealth providers must not abbreviate. When counseling patients about direct-to-consumer GLP-1 options, I emphasize that convenience should never come at the expense of baseline metabolic assessment, medication interaction review, and establishing realistic expectations about the timeline to therapeutic effect. The real clinical advantage here isn’t just availability, it’s that patients who might otherwise delay treatment due to access barriers can now begin their metabolic journey more promptly. My key message to patients exploring these platforms is straightforward: choose a provider who will order your labs, ask detailed questions about your medical history, and commit to quarterly follow-ups rather than simply rubber-stamping a prescription.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: